Impact of additional anticoagulant therapy on thromboembolic events for patients with lung cancer
| Number of subjects | Number of events | Anticoagulation vs Control effect | Heterogeneity | |||||
|---|---|---|---|---|---|---|---|---|
| Variables | Anticoagulation/control (Number of studies) | Anticoagulation (%)/ control (%) | RR (95% CI) | Z | p Value | χ2 | p Value | I2 (%) |
| Overall VTE* | 509/386 (3) | 20 (3.9)/28 (7.3) | 0.55 (0.31 to 0.97) | 2.05 | 0.04 | 0.18 | 0.91 | 0 |
| Symptomatic VTE | 509/386 (3) | 15 (2.9)/20 (5.2) | 0.56 (0.29 to 1.09) | 1.70 | 0.09 | 0.26 | 0.88 | 0 |
| Thromboembolic events | 509/386 (3) | 20 (3.9)/32 (8.3) | 0.48 (0.28 to 0.82) | 2.65 | 0.008 | 0.06 | 0.97 | 0 |
*Asymptomatic and symptomatic VTE. Thromboembolic events include deep vein thrombosis, pulmonary embolism, visceral venous thrombosis, stroke and peripheral thrombosis.
RR, risk ratio; VTE, venous thromboembolism.